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Abstract
Background: Previous exposures to flu and subsequent immune responses may impact on 2009/2010 pandemic
flu vaccine responses and clinical symptoms upon infection with the 2009 pandemic H1N1 influenza strain.
Qualitative and quantitative differences in humoral and cellular immune responses associated with the flu
vaccination in 2009/2010 (pandemic H1N1 vaccine) and natural infection have not yet been described in detail. We
designed a longitudinal study to examine influenza- (flu-) specific immune responses and the association between
pre-existing flu responses, symptoms of influenza-like illness (ILI), impact of pandemic flu infection, and pandemic
flu vaccination in a cohort of 2,040 individuals in Sweden in 2009–2010.
Methods: Cellular flu-specific immune responses were assessed by whole-blood antigen stimulation assay, and
humoral responses by a single radial hemolysis test.
Results: Previous seasonal flu vaccination was associated with significantly lower flu-specific IFN-γ responses (using
a whole-blood assay) at study entry. Pandemic flu vaccination induced long-lived T-cell responses (measured by
IFN-γ production) to influenza A strains, influenza B strains, and the matrix (M1) antigen. In contrast, individuals with
pandemic flu infection (PCR positive) exhibited increased flu-specific T-cell responses shortly after onset of ILI
symptoms but the immune response decreased after the flu season (spring 2010). We identified non-pandemic-flu
vaccinated participants without ILI symptoms who showed an IFN-γ production profile similar to pandemic-flu
infected participants, suggesting exposure without experiencing clinical symptoms.
Conclusions: Strong and long-lived flu-M1 specific immune responses, defined by IFN-γ production, in individuals
after vaccination suggest that M1-responses may contribute to protective cellular immune responses. Silent flu
infections appeared to be frequent in 2009/2010. The pandemic flu vaccine induced qualitatively and quantitatively
different humoral and cellular immune responses as compared to infection with the 2009 H1N1 pandemic H1N1
influenza strain.
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Background
The 2009 H1N1 pandemic H1N1 influenza (flu) A
(pdmH1N1) was first reported in Mexico and California
[1]. As the virus spread globally, it became evident that
the infection was of moderate severity with a broad clin-
ical spectrum of symptoms [2]. Early data from Mexico
suggested that pdmH1N1 may cause severe respiratory
illness in otherwise healthy young and middle-aged
people [3]. It is now estimated that in the United States
pdmH1N1 caused higher rates of hospitalizations and
deaths in children and adults 18–64 years of age than
the flu of the previous season, but lower rates of clinical
events in adults over 65 years of age [4]. This finding
supports the notion that previous exposures to H1N1 in
older individuals provides higher cross-protective immune
responses than in younger individuals [5]. In the autumn
of 2009, pdmH1N1 vaccines (pdm vaccines) were available
across the globe, it was estimated that pdmH1N1 vac-
cination prevented 4,000–10,000 hospitalizations and
200–500 deaths in the US [6].
There are several unanswered questions concerning
H1N1 flu infection and vaccination. Firstly, the impact
of previous immune responses induced by flu vaccina-
tions or by flu exposures on the ability to mount new
anti-flu immune responses [7-9]. It is therefore of inter-
est to map the adaptive humoral and cellular immune
response prior to vaccination and prior to the onset of
flu symptoms. Secondly, the differential quality and
quantity of humoral and cellular immune responses di-
rected against flu targets, induced either by flu vaccin-
ation or by flu infection, has not been well defined.
Thirdly, several reports have discussed a ‘silent infection’
with H1N1 (in non-vaccinated participants), yet the real
extent of such a silent infection is difficult to determine—
in part due to cross-reacting antibodies (Abs) (from pre-
vious exposures or vaccines) [10]. Antibodies, as well as
CD4+ and cytotoxic CD8+ T-cell immune responses,
play a critical role in the host defense against flu [11,12].
Increased cellular reactivity to flu, defined by IFN-γ
production—a key cytokine in the pro-inflammatory re-
sponse to flu—in participants who have not experienced
influenza-like (ILI) symptoms, has not been determined
up to now, this may help to identify silent flu infection.
In order to address these questions, we designed a
prospective study of participants living in the Stockholm
area in the context of the LifeGene (LG) project [13] to
map in detail the breadth of the cellular immune re-
sponses prior to the onset of ILI symptoms and prior to
vaccination with the pdm flu vaccine to study i) pre-
existing immune responses, ii) the association of ILI
symptoms with vaccination, iii) cellular immune reactiv-
ity during the flu season 2009–2010, directed against a
broad panel of flu pathogens. This prospective study was
designed to decipher differences in immune responses
induced by infection with pdmH1N1 and the pdm vac-
cine, and this is the first report to describe in an unbiased
fashion humoral and cellular immune responses during
the pdmH1N1 infection in 2009–2010 in Sweden.
Methods
Study participants
2,040 study participants from Stockholm (Sweden) en-
tered the baseline step of the ILI study in September 2009,
a part of the LG project [13]. For details see the Additional
file 1: Text Material S1. Serum and heparin blood samples
were drawn at study entry and after the flu season in the
spring of 2010. Prepaid envelopes and nasal swabs were
provided to participants after they had received instruc-
tions at the LifeGene study centres before study entry.
Participants contacted the LG centres at the onset of ILI
symptoms, filled out a questionnaire and mailed the (viral)
swab for PCR analysis as described in detail in the supple-
mentary data sets. If swabs tested positive for flu or cor-
onavirus RNA, a home visit was payed during which an
additional nasal swab and a blood sample from the index
study participant and the household members was ob-
tained. (The mean time between the first swab and the
home visit was 2.5 weeks). The study was approved by the
Ethics committee Stockholm south review board (DN
2009/1183-31) and each study participant provided in-
formed consent. Swedish residents were offered the pdm
vaccine Pandemrix (GSK) containing A/ H1N1/California/
7/2009 (with AS03 adjuvant, i.e. DL-α-tocopherol, squa-
lene and polysorbate).
Functional T-cell assay - whole-blood antigen stimulation
assay
Forty μL of heparinised blood was diluted 1:5 in RPMI
1640 with L-glutamine (2 mM), penicillin (100 IU/mL)
and streptomycin (10 mg/mL), and processed as described
in detail in the supplementary data section (Additional
file 1). The whole-blood antigen (WBA) stimulation assay
measures the ‘net’ IFN-γ production elaborated by CD4+
and CD8+ T-cells in whole blood and reflects the activity
of memory T-cell responses. We tested several flu antigens
from previous monovalent flu vaccines, composed of
haemagglutinin (HA) and neuraminidase (N) from flu A




4/2006, or A/H5N1/Vietnam/1203/2004, all provided
by Baxter Innovations GmbH (Vienna, Austria). They
were used at a final concentration of 2.5 μg/mL HA. We
also tested the flu matrix antigens M1 and M2 present as
peptides, and used at a final concentration of 1 μg/mL. As
control, we used the CFP-10 antigen from Mycobacterium
tuberculosis. We could not include the A/H1N1/California/
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7/2009 antigens in the cellular assays, since the test plates
had to be prepared in advance due to quality control issues
to ensure batch-to-batch consistency; the pdmH1N1 anti-
gen preparation was not yet available in the summer of
2009 and the assay worked only with freshly obtained
heparinised blood. In contrast to the cellular assay, Ab titres
could be tested retrospectively.
Swab processing and PCR analysis
If study participants experienced symptoms of ILI, they
performed a nasal swab to be tested for 22 viral targets
(Additional file 1: Table S1) as described [14]. Swab pro-
cessing and PCR are described in detail in the supplemen-
tary data section (Additional file 1: Text Material S1). This
step was taken to link ILI symptoms with the detection of
defined viral pathogens. In addition, if the PCR tested
positive for H1N1, a nurse visited the participant 14 days
(on average) after onset of symptoms in order to obtain a
blood sample, which allowed study of the humoral and
cellular immune response early after infection. This was
also performed for participants infected with coronavirus
as a control group.
Ab determination - single radial haemolysis test
Sera, collected at study entry and after the flu season in
the spring of 2010, and during a home visit in case of a
positive H1N1 or coronavirus PCR (detected from a nasal
swab), were stored at −80°C until testing. Single radial
haemolysis (SRH) test against A/H1N1/California/07/2009
was performed at the Department of Physiopathology, Ex-
perimental Medicine and Public Health of the University
of Siena according to procedures described in detail else-
where [15]. Diameters of the haemolysis area for each
serum tested were measured. Sera with areas of haemoly-
sis equal to or higher than 4 mm2 but lower than 25 mm2
were considered to indicate seropositivity but not protec-
tion; haemolysis areas equal to or higher than 25 mm2
were considered to indicate seroprotection.
Statistical analysis
Statistical analysis was performed on (i) the IFN-γ concen-
trations as a cellular response to flu and non-flu antigens,
(ii) the PCR-based virus detection, (iii) the SRH Ab data,
and (iv) the questionnaire data including symptoms re-
ported in a web-based questionnaire by the study partici-
pants during and after the flu season. Data were analysed
using SAS 9.2 software (SAS Institute). Descriptive statis-
tics were used and Spearman analysis for independence
was performed to verify integrity of data. Significance ana-
lysis was performed using the Pearson χ2-test, Student’s
t-test, and the Wilcoxon-Mann–Whitney two-sample
rank-sum test. Multivariate operations, including opera-
tions on stratified variable dependencies and cluster
analysis (using the VARCLUS procedure), were used in
the analysis based on the combined dataset constitu-
ents, i.e. IFN-γ, PCR, antigen-specific Abs, symptoms,
and vaccination. For each analysis, the nature of the
statistical test used is indicated in the corresponding
figure legend and table.
Results
Study cohort
After quality control (i.e. exclusion of samples without
identification), the analysis group consisted of 1,971 par-
ticipants: 1,807 adults aged between 18 and 65 years (me-
dian age 36, 53% women), 155 adults over 65 (median age
71 years, 65% women), and 9 children with a median age
of 8 years. The baseline step (autumn/winter 2009) is des-
ignated time point ‘A’, and the event step (autumn/winter
2009) is designated time point ‘B’. Altogether, 466 study
participants mailed a swab for viral pathogen analysis and
618 participants filed a self-report (flu event question-
naire). For 41 study participants, a positive H1N1 or
coronavirus PCR (for controls) triggered a home visit
from a nurse to study the immune response at an early
time point. The final step (spring 2010) is designated
time point ‘C’, where 918 study participants (46.6% of
the initial number of participants) again provided a
blood sample (see overview of the study in Figure 1).
This allowed us to study the humoral and cellular im-
mune responses directed against flu—and also against
control antigens—in an unbiased way.
PdmH1N1 ‘swine flu’ RNA could be detected in 27
swabs (24 from study participants and 3 from household
members), and coronavirus RNA could be detected in 53
swabs (from 51 study participants and 2 household mem-
bers) (see overview of the swabs analysis in Additional
file 1: Table S2).
The initial set-point of A/H1N1/California/7/2009-specific
antibodies and IFN-γ production
Study participants reported their flu vaccination status
in the web questionnaires: 25.3% of study participants
had received at least a single previous seasonal flu vac-
cination between 2006 and 2009; 63.1% (n = 755) of the
study participants who responded to the follow-up ques-
tionnaire in the spring received the pdm flu vaccine in
2009–2010.
We evaluated the impact of previous flu vaccinations
on IFN-γ production and A/H1N1/California/7/2009-
specific Ab levels measured by SRH at study entry
(Table 1). The analysis showed significantly lower levels of
IFN-γ production in response to A/H1N1/Brisbane/59/
2007, A/H1N1/Solomon Islands/3/2006 and B/Florida/4/
2006 in blood from study participants who had previously
received seasonal flu vaccination (during the period 2006
to spring 2009) and who did not receive the pdm flu vac-
cine, than in those without any seasonal flu (or pdm)
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vaccination during the same period (p ≤ 0.04). We could
not detect any significant differences in levels of A/H1N1/
California/7/2009-specific Abs between vaccinated and
unvaccinated participants. Notably, both groups were con-
sidered seropositive at SRH > 4 mm2, but below protect-
ive levels (SRH < 25 mm2), at time point A (Table 1).
Additionally, for time point A, we measured by the flu
hemagglutination inhibition assay the presence of Abs
directed against: A/H1N1/California/7/2009, A/H1N1/
Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006, A/
H3N2/Uruguay/716/2007 and A/H5N1/Vietnam/1203/
2004 in 7 participants (above 50 years of age) who had
received previous seasonal flu vaccination, and 7 age-
matched participants who had not received previous sea-
sonal flu vaccination. Interestingly, 2 and 3 participants
(out of 7 participants who did not receive seasonal flu
Table 1 Mean values of A/H1N1/California/7/2009-specific Abs (measured by SRH) and IFN-γ production (in whole-blood
assay) before (A) and after (C) the 2009–2010 flu season, in blood from study participants with our without seasonal flu
vaccination (2006–2009)
Time point A C A C
2006-2009 seasonal flu vacc.
Vacc. Not vacc. Vacc. Not vacc. V/NV1-diff.
SRH (mm2), geometric mean (C.I.) p-value
A/H1N1/California 18.3 (14.2–23.7) 19.6 (17.5–22.0) 19.1 (15.5–23.6) 21.2 (19.2–23.4) 0.5 0.5
IFN-γ (pg/mL), mean
A/H1N1/Brisbane 99 144 168 172 0.04 0.6
A/H1N1/Solomon 85 122 152 153 0.03 0.3
A/H3N2/Uruguay 137 190 221 245 0.12 0.3
A/H3N2/Wisconsin 162 206 226 261 0.3 0.2
A/H5N1/Vietnam 325 361 377 373 0.4 0.9
B/Florida 204 265 260 289 0.04 0.4
B/Malaysia 154 173 164 212 0.14 0.2
M1 24 37 35 33 0.14 0.14
M2 18 18 19 21 0.7 0.7
CFP-10 20 22 18 23 0.4 0.3
PHA 518 512 545 544 0.6 0.5
N 57 175 57 175
Mean age, years 50 38 50 38 <0.001 <0.001
The Wilcoxon-Mann–Whitney rank-sum test was used to calculate p-values. 1V/NV: vaccinated vs. unvaccinated. Listed are Ab responses (top panel, directed
against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a broad panel of flu targets (designated the flu A or flu B strains),
and against matrix proteins M1 and M2. CFP10 served as a control. PHA was the positive control stimulus. P values below 0.05 are indicated in bold.
Figure 1 Overview of the ILI study participants. 1,971 study participants entered the study in the winter of 2009 (time point A); 67 samples
were collected from study participants and household members during home visits triggered by an H1N1+ or coronavirus + PCR (detected in
nasal swabs sent at time point B); 918 study participants returned for the follow-up sampling in the spring of 2010 (time point C).
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vaccination) showed measurable levels of Abs specific
for A/H1N1/Brisbane/59/2007 and A/H1N1/Solomon
Islands/3/2006, respectively, but only 1 participant (out
7 participants who had received previous seasonal flu
vaccination) showed measurable levels of Abs specific
for A/H1N1/Solomon Islands/3/2006 (data not shown).
In contrast to the differences observed at entry into
the study (time point A), no differences were observed
in IFN-γ production between study participants with
or without previous seasonal flu vaccinations (Table 1)
at time point C. At this time point, levels of A/H1N1/
California/7/2009-specific Abs were below protective
levels (SRH < 25 mm2) in both vaccinated and unvaccin-
ated participants.
The immunological footprint of pdm vaccination
We followed the study participants who gave blood at
time points A and C and reported (in the spring of 2010)
their 2009–2010 pandemic vaccination status. At time
point A, the levels of A/H1N1/California/7/2009-specific
Abs and IFN-γ production in response to the flu anti-
gens were comparable between participants who re-
ceived (after time point A) the pdm flu vaccine and
individuals who chose not to receive the vaccine (sero-
positive at SRH > 4 mm2, but below protective levels
(SRH < 25 mm2)).
At time point C, the levels of A/H1N1/California/7/
2009-specific Abs were above protective levels (SRH ≥
25 mm2) in pdm flu vaccinated participants, the Ab levels
were significantly higher (p < 0.001) than in non-pmd flu
vaccinated study participants. We also observed a statisti-
cally significant increase in IFN-γ production in response
to all flu antigens (except for B/Malaysia/2506/2004), in-
cluding the flu matrix antigen M1, in blood from study
participants who received the pdm flu vaccine in the win-
ter of 2009–2010 compared to the non-vaccinated study
participants (p ≤ 0.04) (Table 2; note that M1 is not a des-
ignated component of the flu vaccine).
Experience of ILI symptoms and the effect of pdm flu
vaccination
We examined whether ILI symptoms segregated with
the flu vaccination records. 58.0% of study participants
who were vaccinated also reported the experience of ILI
symptoms. 65 study participants who received the pdm
flu vaccine and filed their ILI symptoms report later
during the flu season (i.e. after December 2009, and
after they had received the pdm flu vaccine) experi-
enced significantly more symptoms than the 170 study
participants who did not receive the pdm flu vaccine
(and also reported their ILI symptoms after December
2009). Vaccinated study participants reported 4 ILI
Table 2 Mean values of A/H1N1/California/7/2009-specific Abs (measured by SRH) and IFN-γ production in the
whole-blood assay before (A) and after (C) the 2009/2010 flu season in study participants with our without pdm flu
vaccination
Time point A C A C
pdm vaccination
Vacc. Not vacc. Vacc. Not vacc. V/NV1-diff.
SRH (mm2), geometric mean
A/H1N1/California 20.1 (18.5–21.8) 19.3 (17.3–21.4) 27.9 (26.4–29.5) 20.7 (18.9–22.6) 0.3 <0.001
IFN-γ (pg/mL), mean
A/H1N1/Brisbane 139 133 285 169 0.3 <0.001
A/H1N1/Solomon 119 113 246 151 0.2 <0.001
A/H3N2/Uruguay 194 177 304 238 0.2 <0.001
A/H3N2/Wisconsin 203 195 301 251 0.6 <0.01
A/H5N1/Vietnam 346 352 423 373 0.6 <0.01
B/Florida 221 250 245 283 0.1 0.04
B/Malaysia 145 168 167 200 0.15 0.07
M1 33 34 63 34 0.8 <0.01
M2 18 18 20 20 0.4 0.8
CFP-10 21 21 24 22 0.7 0.2
PHA 501 513 506 545 0.13 0.02
N 437 232 437 232
Mean age, years 47 41 47 41 <0.001 <0.001
The Wilcoxon-Mann–Whitney rank-sum test was used to calculate p-values. 1V/NV: vaccinated vs. unvaccinated. Listed are Ab responses (top panel, directed
against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a broad panel of flu targets (designated the flu A or flu B strains),
and against matrix proteins M1 and M2. CFP10 served as control. PHA was the positive control stimulus. P values below 0.05 are indicated in bold.
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symptoms rather than 3 symptoms on average, i.e. nasal
discharge (p = 0.02), fatigue (p = 0.04), cough (p = 0.01),
sneezing (p = 0.04) and chills (p = 0.05) (Table 3). The
45 study participants who received the pdm flu vaccine
and mailed a swab later showed less frequent detection
(6/45) of coronavirus RNA (p = 0.03), but showed a
higher percentage (14/45) of rhinovirus RNA (p = 0.01)
in their nasal swabs as compared to the 139 study par-
ticipants who chose not to get vaccinated but mailed a
swab due to symptoms of ILI (44/139).
IFN-γ production profiles and A/H1N1/California/7/
2009-specific Abs showed differences in unvaccinated
and vaccinated study participants depending on their ILI
symptom status
We analysed the immune status from study participants
who did not report any symptoms of ILI since they were
either (i) not exposed to pathogens leading to ILI symp-
toms, (ii) they may have been protected due to pre-
existing anti-flu directed immune responses or pdm flu
vaccination.
We show in Table 4 significant differences (time point
C versus time point A) in IFN-γ production and A/
H1N1/California/7/2009-specific Abs in blood samples
from study participants who received the pdm flu
vaccine and reported no ILI symptoms versus blood
samples from unvaccinated study participants (report-
ing no ILI symptoms). At time point C (i.e. after the
flu season) we identified higher levels of A/H1N1/
California/7/2009-specific Abs (p < 0.001) and IFN-γ
production in response to A/H5N1/Vietnam/1203/2004
(p = 0.03), to A/H1N1/Brisbane/59/2007, to A/H1N1/
Solomon Islands/3/2006 (p < 0.001) as well as to the M1
matrix antigen (p < 0.01) in study participants who
received the pdm flu vaccine.
Next, we examined IFN-γ production and A/H1N1/
California/7/2009-specific Abs in blood from study par-
ticipants (vaccinated and non-vaccinated) who reported
ILI symptoms (Table 5). We identified a slightly different
immunological reactivity pattern as compared to the
group of study participants who did not report any ILI
symptoms at all (see above): (i) the increase (between
time point C and time point A) in the mean value of A/
H1N1/California/7/2009-specific Abs in unvaccinated
and vaccinated study participants was not statistically
significant, yet it reached protective levels (>25 mm2) at
time point C for pdm flu vaccinated study participants (ii)
vaccinated study participants showed a significant increase
in IFN-γ production in response to A/H1N1/Brisbane/59/
2007 (p < 0.001), to A/H3N2/Uruguay/716/2007, to A/
H1N1/Solomon Islands/3/2006 (p ≤ 0.01), and to A/
H3N2/Wisconsin/67/2005 (p = 0.02).
The immunological profile of H1N1 infection
We analysed in greater detail the IFN-γ production and
A/H1N1/California/7/2009-specific Abs from 21 study
participants who tested positive for pdmH1N1 RNA and
received a home visit (time point B) after the ILI symptom
Table 3 Reported distribution of symptoms in study participants with or without pdm flu vaccination
Symptoms Vaccinated Not vaccinated Difference
N % N % p-value
Nasal discharge 43 15.1 84 14.8 0.02
Fatigue 36 12.6 68 12.0 0.04
Cough 35 12.3 61 10.7 0.01
Headache 28 9.8 62 10.9 0.4
Sneezing 35 12.3 66 11.6 0.04
Sore throat 23 8.1 65 11.4 0.7
Muscle aches or joint pain 26 9.1 48 8.4 0.08
Chills 22 7.7 36 6.3 0.05
Other symptoms 9 3.2 20 3.5 0.7
Fever 9 3.2 20 3.5 0.7
Ear pain 7 2.5 21 3.7 0.7
Chest discomfort 6 2.1 9 1.6 0.3
Diarrhea 3 1.1 5 0.9 0.5
Itch 2 0.7 4 0.7 0.8
Vomiting 1 0.4 0 0.0 0.1
Symptoms N/% 285 100 569 100
N 65 65 170 170
Note the differential symptom presentation in participants vaccinated or not vaccinated against pdmH1N1. P values below 0.05 are indicated in bold.
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Table 4 Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in study participants with or
without pdmH1N1 vaccination who did not report any symptoms of ILI during the 2009–2010 flu season
Not vaccinated Vaccinated Difference
A C C-A A C C-A C-A V-N1 p-value
SRH (mm2), geometric mean
A/H1N1/California 20.9 23.3 2.4 18.8 28.6 9.8 7.4 <0.001
IFN-γ (pg/mL), mean
A/H1N1/Brisbane 134 164 30 101 234 134 105 <0.01
A/H1N1/ Solomon 117 142 25 60 190 130 105 <0.001
A/H3N2/Uruguay 167 232 64 148 256 109 37 0.07
A/H3N2/Wisconsin 172 243 71 145 253 108 37 0.4
A/H5N1/Vietnam 338 338 0 307 395 88 88 0.03
B/Florida 233 275 42 196 208 12 −27 0.6
B/Malaysia 155 197 42 125 141 15 −27 0.3
M1 32 29 −3 22 49 27 30 <0.01
M2 18 22 4 18 18 0 −4 0.9
CFP-10 19 18 −1 20 23 3 4 0.2
PHA 501 538 37 517 519 2 −35 0.8
Mean IFN-γ diff. 163 191 28 144 198 53 25
N 94 94 120 120
The Wilcoxon-Mann–Whitney rank-sum test was used to calculate the p-values (comparison of C-A between vaccinated and unvaccinated). 1V-N is vaccinated
minus unvaccinated. Listed are Ab responses (top panel, directed against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a
broad panel of flu targets (designated the flu A or flu B strains), and against matrix proteins M1 and M2. CFP10 served as control. PHA was the positive control
stimulus. P values below 0.05 are indicated in bold.
Table 5 Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in study participants with or
without pdmH1N1 vaccination who reported symptoms of ILI during the 2009–2010 flu season
Not vaccinated Vaccinated Difference
A C C-A A C C-A C-A V-N1 P-value
SRH (mm2), geometric mean
A/H1N1/California 15.3 19.5 4.2 18.8 28.0 9.2 5.0 0.1
IFN-γ (pg/mL)
A/H1N1/Brisbane 169 166 −2 113 296 183 185 <0.001
A/H1N1/Solomon 130 180 50 80 262 182 132 <0.01
A/H3N2/Uruguay 197 250 53 177 336 159 106 0.01
A/H3N2/Wisconsin 217 248 32 185 343 157 125 0.02
A/H5N1/Vietnam 330 374 44 310 403 93 49 0.3
B/Florida 254 276 22 177 263 85 63 0.4
B/Malaysia 173 203 30 108 208 101 71 0.08
M1 43 34 −10 31 62 31 41 0.09
M2 18 18 0 18 18 0 0 0.3
CFP-10 18 20 2 22 19 −3 −5 0.7
PHA 505 557 53 498 536 39 −14 0.9
Mean IFN-γ diff. 168 200 33 146 230 84 51
N 49 49 47 47
The Wilcoxon-Mann–Whitney rank-sum test was used to calculate the p-values (comparison of C-A between vaccinated and unvaccinated). 1V-N is vaccinated
minus unvaccinated. Listed are Ab responses (top panel, directed against A/H1N1 California, mean and confidence interval) and IFN-γ responses directed against a
broad panel of flu targets (designated the flu A or flu B strains), and against matrix proteins M1 and M2. CFP10 served as control. PHA was the positive control
stimulus. P values below 0.05 are indicated in bold.
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report (Table 6); biological material from participants who
tested positive for coronavirus RNA served as controls.
Blood from participants with a positive pdmH1N1 PCR
(but not the coronavirus positive controls), showed signifi-
cantly higher levels of A/H1N1/California/7/2009-specific
Abs (p ≤ 0.001) at time point B and at time point C (as
compared to time point A, i.e. before the flu season). Par-
ticipants testing positive for pdmH1N1 RNA also showed
significantly higher levels of IFN-γ production at time
point B than at time point A (p ≤ 0.01) in response to all
flu antigens including M1, except for B/Florida/4/2006
and B/Malaysia/2506/2004.
We observed significantly higher levels of IFN-γ pro-
duction in response to only 3 flu antigens: A/H3N2/
Wisconsin/67/2005, A/H1N1/Brisbane/59/2007 and A/
H1N1/Solomon Islands/3/2006 in the flu season (time
point C) as compared to the time point zero samples
(timepoint A). Thus, the cellular immune response to
the H1N1 infection was short-lived, it was directed
against a broad panel of flu targets, defined by strong
IFN-γ production and pronounced shortly after onset of
symptoms (i.e. at the time of the home visit). This was
not found to be true several months after the infection:
the cellular immune response, defined by IFN-γ produc-
tion, was weaker and directed only against a narrow
panel of flu targets (time point C).
Next, we examined differences between IFN-γ produc-
tion and A/H1N1/California/7/2009-specific Abs at time
points A and C from (i) study participants who received
the pdm flu vaccine and reported no ILI symptoms, and
from study participants who did not receive the pdm flu
vaccine and whose swab results did not test pdmH1N1
PCR positive and (ii) either reported at least one ILI or
(iii) reported no ILI symptoms (Table 7).
We observed significantly increased levels (between
time points A and C; p ≤ 0.003) of A/H1N1/California/7/
2009-specific Abs in blood from participants who tested
positive for H1N1 (and did not receive pdm vaccination;
mean increase in Ab titre (SRH): 14.5), and from study
participants who received the pdm vaccine (mean increase
in Ab titre (SRH): 8). A/H1N1/California/7/2009-specific
Abs were above protective levels (>25 mm2) for those both
groups (vaccinated or non-vaccinated) at time point C.
No significant difference between time points A and C
(before and after the flu season) concerning A/H1N1/
California/7/2009-specific antibody levels was observed in
the group of participants who either tested negative for
H1N1 or received flu vaccination (regardless of the re-
ported ILI symptom status); both groups were seropositive
but exhibited antibody titres below protective levels.
We observed a very similar IFN-γ production profile
in blood from participants who (i) did not receive the
Table 6 Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in study participants who tested
positive for H1N1 or coronavirus
H1N1 positives Corona positives HCB HCC
A B C AB1 AC1 A B C AB1 AC1 p
SRH (mm2), geometric mean p-value SRH (mm2), geometric mean p-value
A/H1N1/California 16.1 46.9 30.6 <0.001 0.003 21.1 29.8 24.3 0.2 0.4 <0.001 0.001
IFN-γ (pg/mL)
A/H1N1/Brisbane 90 460 274 <0.001 0.01 156 227 159 0.6 0.2 <0.001 0.01
A/H1N1/Solomon 104 416 272 <0.001 0.01 124 212 159 0.2 0.2 <0.01 0.03
A/H3N2/Uruguay 125 420 292 <0.001 0.09 222 224 244 0.8 0.4 <0.001 0.09
A/H3N2/Wisconsin 137 408 298 <0.001 0.02 212 236 242 0.5 0.4 0.001 0.04
A/H5N1/Vietnam 316 546 392 <0.01 0.3 355 394 367 0.7 0.8 <0.01 0.3
B/Florida 218 307 327 0.24 0.2 216 370 240 0.08 0.7 0.4 0.1
B/Malaysia 173 260 251 0.06 0.25 160 249 177 0.2 0.5 0.7 0.11
M1 34 127 48 <0.01 0.08 18 24 25 0.04 0.15 0.07 0.25
M2 19 18 19 0.3 0.9 18 18 18 0.9 0.9 0.4 0.9
CFP-10 19 25 18 0.9 0.3 18 18 18 0.6 0.3 0.9 0.7
PHA 502 535 588 0.9 0.08 524 589 544 0.1 0.5 0.2 0.25
Mean IFN-γ diff. 148 265 233 173 220 189
N 21 21 21 38 15 38
The Wilcoxon-Mann–Whitney rank-sum test was used to calculate the p-values. AB1: difference between time point A and B; AC1: difference between time point A
and C; HCB: difference between pdmH1N1 positive and coronavirus positive at time point B. HCC difference between pdmH1N1 positive and coronavirus positive
at time point C. Note the strong immune responses at time point B in participants with pdmH1N1 infection; this response was reduced at the end of the study
(time point C). P values below 0.05 are indicated in bold.
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pdm flu vaccination, (ii) tested negative for pdmH1N1 and
(iii) reported no ILI symptoms compared to those who
tested H1N1 positive: increased IFN-γ production in re-
sponse to the flu antigens A/H1N1/Brisbane/59/2007, A/
H1N1/Solomon Islands/3/2006, A/H3N2/Wisconsin/67/
2005 and A/H3N2/Uruguay/716/2007 (p ≤ 0.04).
Discussion
This study showed that pdm flu vaccination (A/California/
7/2009) induced increased levels of A/H1N1/California/7/
2009-specific Abs, but also strong immune cellular re-
sponses (measured by IFN-γ production in a whole-blood
assay) directed against flu A antigens from H1N1, H3N2
and H5N1 strains, flu B strains, and the flu M1 matrix
antigen.
We have not been able to include the pdm flu strain.
However, increased IFN-γ production after vaccination
suggested that A/California/7/2009-specific T-cell re-
sponses were induced by pdm flu vaccination. This
would imply that pdm flu vaccine induced (cross)-re-
active cellular responses did not only target the flu A
H1N1 strains, but also H3N2, H5N1 and flu B strains.
In agreement with this observation, we showed that
participants who received the pdm flu vaccination ex-
hibited also a significant increase in Ab titers directed
against A/H1N1/Solomon Islands/3/2006 and A/H5N1/
Vietnam/1203/2004, while participants who did not re-
ceive the pdm flu vaccine exhibited only a significant
increase in A/H1N1/California/7/2009-specific Abs but
not in Abs against the other flu A strains tested by the flu
hemagglutination inhibition assay (data not shown).
The flu vaccine, studied in this report, represents a
split virus vaccine, which is mainly composed of surface
membrane glycoproteins, yet traces of M1 have also
been detected [16] as part of the vaccine formulation.
We tested M1 and M2 as targets for cellular immune
responses in the current study. The M2 protein is a
proton-selective ion channel protein, integral in the
viral envelope of the influenza A virus. M2 brings pro-
tons into the virion core. Acidification of virus interior,
leads to weakening of electrostatic interaction and leads
to dissociation between M1 (matrix protein) and viral
rib nucleoprotein (RNP) complexes [17]. Traces of M1
in the split vaccine may be responsible for the strong
anti-M1 directed responses defined by IFN-γ production,
which has not been reported until now. Flu vaccines are
produced and standardised based on their haemagglutinin
and neuraminidase content, and traces of the M1 proteins,
contained in the current standard vaccines, may in part be
responsible for conferring protective immune responses
between flu A strains, since the M1 protein is quite con-
served [18]. The M1-directed cellular immune responses,
along with traces of M1 proteins in split vaccines may
in part responsible for the cross-reactive immune re-
sponses against H5N1 associated with the pdm flu vac-
cine, since CD4+ and CD8+ T-cell responses directed
against H5N1 have preferentially reported to focus on
M1 or NP (nucleoproteins) [19].
Table 7 Mean values of A/H1N1/California/7/2009-specific Abs and IFN-γ production in blood from study participants
with or without pdm flu vaccination and reported either symptoms or no symptoms of ILI
Vacc + & Sym+ Vacc + & Sym- Vacc- & Sym+ Vacc- & Sym-
A C P A C P A C p A C P
SRH (mm2), geometric mean
A/H1N1/California 20.6 28.7 <0.001 20.4 28.2 <0.001 14.8 18.1 0.4 20.4 20.7 0.9
IFN-γ (pg/mL)
A/H1N1/Brisbane 126 339 <0.001 115 279 <0.001 156 163 0.2 128 158 0.04
A/H1N1/Solomon s/3/2006 97 293 <0.001 90 231 <0.001 121 164 0.2 108 140 0.001
A/H3N2/Uruguay 195 350 <0.001 162 297 <0.001 224 256 0.3 170 233 <0.01
A/H3N2/Wisconsin 207 346 <0.001 170 294 <0.001 247 264 0.4 200 245 0.04
A/H5N1/Vietnam 346 426 0.03 325 427 <0.001 336 382 0.3 347 363 0.7
B/Florida 231 316 0.04 202 230 0.06 280 286 0.8 230 267 0.09
B/Malaysia 138 204 0.03 129 163 <0.01 191 221 0.4 157 183 0.1
M1 31 81 <0.01 27 51 <0.001 37 26 0.3 30 36 0.5
M2 18 18 0.3 18 20 0.03 18 18 0.3 18 20 0.5
CFP-10 21 19 0.3 22 24 0.4 18 18 0.9 21 22 0.5
PHA 513 521 0.3 495 513 0.05 500 546 0.15 516 534 0.3
Mean IFN-γ 165 240 151 211 173 199 164 192
N 69 69 312 312 48 48 208 208
The Wilcoxon-Mann–Whitney rank-sum test was used to calculate the p-values (difference between time point A and B). Note the increased antigen-specific
cellular immune responses in blood from participants who did not receive the vaccine and did not report any ILI symptoms. P values below 0.05 are indicated in bold.
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In addition, we showed at study entry that previous
seasonal flu vaccination (in 2006–2009) did not lead to
an increased IFN-γ production in response to flu antigen
components from 2006–2009 flu vaccines, but was instead
associated with significantly lower IFN-γ production in re-
sponse to flu antigen components from 2008–2009 flu
vaccines (A/H1N1/Brisbane/59/2007, A/H1N1/Solomon
Islands/3/2006 and B/Florida/4/2006). A similar trend was
observed when analysing H1N1/Brisbane/59/2007- and
A/H1N1/Solomon Islands/3/2006-specific antibodies.
However, at the end of the study, we could not detect
significant differences in IFN-γ production in response
to flu antigens between previously vaccinated and unvac-
cinated participants. This suggests that after the flu sea-
son, previously vaccinated and unvaccinated participants
were able to mount comparable immune responses (as
measured by IFN-γ production in the whole-blood assay).
A recent report showed that individuals with a history
of seasonal flu vaccination exhibited after natural pdm flu
infection or pdm flu vaccination a skewed Ab response to-
wards previously encountered flu antigens, further proving
the impact of previous flu vaccination on subsequent in-
fection or vaccination [20]. Seasonal flu vaccination of
children has been reported to interfere with the develop-
ment of heterosubtypic immunity [21] and Ab responses
to pandemic H1N1 appeared to be reduced in participants
who received seasonal flu vaccination 3 months prior to
vaccination with the pmd flu vaccine [22]. The report by
Skowronski and co-workers also suggested an association
between the previous 2008–2009 flu vaccination and pan-
demic H1N1 illness in Canada [23]; the mechanisms
underlying this finding are ill-defined and warrant further
research to better understand the impact of seasonal flu
vaccination, i.e. the potential ‘negative imprint’ of previous
vaccinations on cellular immune memory responses.
Reservations about flu vaccination, including the no-
tion that flu vaccination would not result in appropriate
protection, have been discussed in the public domain
[24-26]. One of the arguments is that flu vaccination
may not protect against ILI symptoms during flu the sea-
son. This notion was corroborated in our study. A num-
ber of study participants, after pdm flu vaccination,
experienced more ILI symptoms, perhaps due to the ob-
served increase in prevalence of rhinovirus infection in
pdm flu vaccinated participants as compared to non-
pdm flu vaccinated participants. Other reasons may ac-
count for these observations, one of them being the low
predictive value of the ILI case definition [26]. Future
prospective studies may address the question whether
certain flu vaccines are able to increase cellular immune
responses in the respiratory system, particularly after en-
counter with the wildtype flu. Increased ‘influenza-like’
symptoms may occur upon exposure to additional path-
ogens, such as rhino- or coronavirus, that stimulate
‘flu-primed’ innate or adaptive immune responses. This
hypothesis is supported by the observation that infection
with rhinovirus may have delayed the circulation of
H1N1, most likely via activation of non-specific innate
immune responses in the respiratory system [27].
Study participants who received the pdm flu vaccine
showed similar IFN-γ production profiles in response to
the flu antigens tested, irrespective of the experience of
ILI symptoms. However, we observed that study partici-
pants who received the pdm flu vaccine and reported ILI
symptoms (compared to non-pdm flu vaccinated partici-
pants with ILI symptoms), showed by the end of the study
a comparable increase in A/California/7/2009-specific Abs
and an increase in IFN-γ production in response to the flu
A H1N1 and H3N2 strains. This immune status could not
be observed in participants who reported no ILI symp-
toms, irrespective of whether or not they received the
pmd flu vaccination. This suggests that some pmd flu vac-
cinated participants who reported ILI symptoms may have
been exposed to the H3N2 seasonal flu supporting previ-
ous observations that pmd flu vaccination did not affect
the rate of H3N2 infections [28]. The pdmH1N1 strain
dominated the flu season in Sweden in 2009–2010, but flu
H3N2 and flu B were also present in 1.7% and 1.4% of the
samples analysed by the Swedish National Influenza
Centre [29].
The comparable increase in A/H1N1/California/7/
2009-specific Abs in serum from unvaccinated and pdm
flu vaccinated study participants who reported ILI symp-
toms also suggests that non-pdm flu vaccinated study
participants may have been exposed to the pdm flu.
We speculate that the non-pdm flu vaccinated study
participants who reported ILI symptoms had been ex-
posed to the pdm flu. These individuals exhibited lower
levels of IFN-γ production in response to the H1N1 and
H3N2 flu antigens as compared to pmd flu vaccinated
study participants who reported ILI symptoms. This
would also fit with the hypothesis that IFN-γ production
directed against related flu antigens upon natural by
pdmH1N1 infection is short-lived as compared to IFN-γ
induced by pdm flu vaccination. This notion was indeed
corroborated: we showed that shortly after a positive
pdmH1N1 PCR, IFN-γ production to most of the flu anti-
gens was significantly increased, yet declined by the end of
the study (May 2010). In contrast, we could detect signifi-
cantly higher levels of IFN-γ production in response to
M1 (which is not a designated vaccine component) at the
end of the study in pdm flu vaccinated participants; this
was not the case for study participants who tested positive
for pdmH1N1 by PCR (Table 6).
Finally, our observation that study participants i) with
a negative pdm flu PCR ii) absent pdm flu vaccination
and iii) a negative ILI symptom report, showed increased
IFN-γ production in response to most of the flu antigens,
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concomitant with the absence of A/H1N1/California/7/
2009-specific Ab increase, suggests that these individuals
may have been exposed to pdm flu, i.e. that they were ‘si-
lently infected’ and developed a strong anti-pdm flu T-cell
(but not a B-cell) response.
Conclusions
The detection of stronger cellular responses measured
after the flu season, directed against M1, from study par-
ticipants who received pdm flu vaccination (as compared
to study participants who had a natural pdm flu infection)
argues for a more detailed analysis of the role of M1-
specific cellular responses induced by vaccination. M1 re-
sponses are currently discussed to be crucial in mediating
protective anti-flu directed immune responses [30] and
may therefore become an important component of future
vaccines. The prospective study layout of the LifeGene ILI
cohort also demonstrates the value of a time point zero
sample to gauge the immune response prior to a vaccin-
ation or exposure: pre-existing humoral and cellular im-
mune responses shape the nature of the immune response
associated with immune protection or immune pathology.
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